A Randomized, Double-blind, Placebo-controlled, Dose-escalating Phase I Clinical Trial

Conditions: Schizophrenia

Interventions: Drug: KR23248; Drug: Matching Placebo

Sponsors: Jiangxi Kvvit Pharmaceutical Co., Ltd.

Not yet recruiting